Biovel Life Science launches operations in India

Bangalore, July 5 (UNI) Biovel Life Sciences, an integrated biotechnology enterprise, today announced launch of its operations in India.

Addressing a press conference here, Biovel Life Sciences Chairman and Managing Director P Sudhakera Naidu said the company would come out with vaccine for Typhoid next year from the state-of-the-art pilot plant set up at Hosakote.

The plant would also produce recombinant proteins like EGF and Streptokinase.

''Biovel is also actively pursuing the development of molecules in segments of oncology, dermatology and gynecology'', he added.

The company, which had collaboration with US based Dowpharma for the production of Human Growth Hormone (HGH) using Pfenex Expression Technology, currently focuses on research, manufacturing and marketing of biogenerics and biopharmaceuticals.

Mr Naidu said the facility spread across ten acres would house a R and D centre, a pilot plant, two independent production lines with 300 L and 100 L fermentors and two independent filling lines with lyophilizzation.

Dowpharma Global Business Director Nick Hyde said the Dowpharma would prepare and transfer to biovel a Research Cell Bank and the bench scale process. This technology was based on specially modified strains of 'Pseudomonas fluorenscens' bacteria.

Biovel Director (Technical) Dr Durgaprasad said "our team of research scientists would enable us to efficiently advance this project, including pre-clinical testing, clinical testing, manufacturing and global marketing." He said the company had a multi-disciplinary research and development center with fully equipped modern infrastructure coupled with highly qualified accomplished scientists.

UNI